STOCK TITAN

Shattuck Labs Inc - STTK STOCK NEWS

Welcome to our dedicated news page for Shattuck Labs (Ticker: STTK), a resource for investors and traders seeking the latest updates and insights on Shattuck Labs.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Shattuck Labs's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Shattuck Labs's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.2%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.23%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.76%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.88%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.44%
Tags
clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.98%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.66%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.01%
Tags
conferences clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
none
Shattuck Labs Inc

Nasdaq:STTK

STTK Rankings

STTK Stock Data

424.42M
30.26M
13.26%
59.87%
3.49%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Austin

About STTK

shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. compounds derived from shattuck’s proprietary agonist redirected checkpoint, arc®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. the company’s lead wholly owned program, sl-172154 (sirpα-fc-cd40l), which is designed to block the cd47 immune checkpoint and simultaneously agonize the cd40 pathway, is being evaluated in a phase 1 trial. a second compound, sl-279252 (pd1-fc-ox40l), is being evaluated in a phase 1 trial in collaboration with takeda pharmaceuticals. additionally, the company is advancing a proprietary gamma delta t cell engager, gadlen™, platform, which is designed to bridge gamma delta t cells to tumor antigens for the treatment of patients with cancer. shattuck has offices in both austin, tex